Empliciti (elotuzumab; Bristol-Myers Squibb/AbbVie) is a monoclonal antibody that targets the signaling lymphocytic activation molecule family, member 7 (SLAMF7), also called CS1. This cell-surface glycoprotein is expressed in high levels on multiple myeloma (MM) cells and normal plasma cells. It is also expressed on natural killer (NK) cells where it functions as an activating receptor. Empliciti induces MM cell death by direct activation of NK cells and through antibody-dependent NK cell-mediated cytotoxicity.
LIST OF FIGURES
13 Figure 1: Empliciti for multiple myeloma – SWOT analysis
14 Figure 2: Datamonitor Healthcare’s drug assessment summary of Empliciti for multiple myeloma
15 Figure 3: Datamonitor Healthcare’s drug assessment summary of Empliciti for multiple myeloma
17 Figure 4: Empliciti sales for multiple myeloma across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
5 Table 1: Empliciti drug profile
7 Table 2: Empliciti pivotal trial data in multiple myeloma
9 Table 3: Empliciti early-phase trial data in multiple myeloma
12 Table 4: Empliciti ongoing late-phase clinical trials in multiple myeloma
18 Table 5: Empliciti sales for multiple myeloma across the US, Japan, and five major EU markets, by country ($m), 2017–26
20 Table 6: Patients treated with Empliciti across the US, Japan, and five major EU markets, by country, 2017–26
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.